SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
European Organisation for Research and Treatment of Cancer - EORTC
4,975 participants
May 3, 2017
OBSERVATIONAL
Conditions
Summary
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Eligibility
Inclusion Criteria6
- Patients with pathologically confirmed selected tumor types (at site or centrally);
- Mandatory availability of adequate human biological material (HBM);
- Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
- Age ≥ 12 years;
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Written informed consent according to applicable legal and ethical requirements;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
WES, lcWGS and RNAseq, multiplex IF and IMC
WES, RNAseq and EPIC array
NGS panel
NGS panel
ctDNA detection and WES
Locations(134)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02834884